Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   94663 News 


«12...4748495051525354555657...10641065»
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Retrospective data, Review, Journal:  Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) -  Apr 27, 2024   
    The benefit of associating anti-CD38 monoclonal antibodies to proteasome inhibitor (PI)/immunomodulatory agent (IA) and dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma (MM) remains unclear...Also, there was a significant increase in non-hematological adverse events, such as dyspnea (RR 1.72; 95% CI 1.38-2.13; p < 0.01) and pneumonia (RR 1.34; 95% CI 1.13-1.59; p < 0.01), in the group treated with anti-CD38 monoclonal antibody. In conclusion, the incorporation of an anti-CD38 monoclonal antibody demonstrated a promising prospect for reshaping the established MM treatment paradigms.
  • ||||||||||  Simdax (levosimendan IV) / AbbVie
    Clinical, Review, Journal:  An Update on Pharmacologic Management of Neonatal Hypotension: When, Why, and Which Medication. (Pubmed Central) -  Apr 27, 2024   
    Anti-hypotensive treatment, which includes dopamine, dobutamine, epinephrine, norepinephrine, milrinone, vasopressin, terlipressin, levosimendan, and glucocorticoids, is a long-established intervention in neonates with arterial hypotension (AH)...In this review, after a short review of AH definitions used in neonates and existing data on pathophysiology of AH, we discuss currently available data on pharmacokinetic and hemodynamic effects, as well as the effectiveness and safety of anti-hypotensive medications in neonates. In addition, data on the comparisons between anti-hypotensive medications and current suggestions for the main indications of each medication are discussed.
  • ||||||||||  dexamethasone / Generic mfg., deferoxamine / Generic mfg.
    Journal:  Nanofiber Hydrogel Drug Delivery System for Prevention of Postsurgical Intestinal Adhesion. (Pubmed Central) -  Apr 27, 2024   
    The in vivo results indicated that NHP can effectively prevent PIA formation by restraining inflammation and vascularization, promoting peritoneal repair. Therefore, we believe that our NHP has a great potential application in inhibition of PIA.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Clinical, Retrospective data, Journal:  A comparative study of general and severe mycoplasma pneumoniae pneumonia in children. (Pubmed Central) -  Apr 27, 2024   
    Our findings suggest that severely ill children have more pronounced inflammatory reaction and extrapulmonary complications. For effective management of children with SMPP, hormonal, prophylactic, anticoagulant therapy, as well as the use of antibiotics other than macrolides for bacterial co-infections, could be incorporated into treatment regimens.
  • ||||||||||  fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
    Clinical, PK/PD data, Journal:  Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability. (Pubmed Central) -  Apr 27, 2024   
    For effective management of children with SMPP, hormonal, prophylactic, anticoagulant therapy, as well as the use of antibiotics other than macrolides for bacterial co-infections, could be incorporated into treatment regimens. In vitro properties were also measured for each batch, and the batch with a higher fraction of the fine particle (diameter?<?1
  • ||||||||||  methylprednisolone acetate / Generic mfg.
    Journal:  Pradofloxacin for Treatment of Bartonella henselae in Experimentally Inoculated Cats. (Pubmed Central) -  Apr 26, 2024   
    In the one month prior to pradofloxacin administration, all cats were PCR-positive for Bartonella DNA on at least two of four sample dates; after pradofloxacin administration, all cats were negative for B. henselae DNA in blood on all nine sample dates. The protocol appears to be safe and failure to amplify B. henselae DNA from the blood after the administration of pradofloxacin and one dose of methylprednisolone acetate suggests either an antibiotic effect or the organism was cleared spontaneously.
  • ||||||||||  tobramycin/dexamethasone / Generic mfg.
    Journal:  Tear film proteome changes following Tobradex therapy in anterior blepharitis. (Pubmed Central) -  Apr 26, 2024   
    Tobradex treatment reversed the expression of plakin proteins in anterior blepharitis. Topical solutions which inhibit the expression of plakin proteins may have the potential to restore the ocular surface integrity in anterior blepharitis and should be explored further.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Clinical, Review, Journal:  At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023? (Pubmed Central) -  Apr 26, 2024   
    Melphalan-prednisone (MP), bortezomib plus MP (VMP), lenalidomide-dexamethasone (Rd), and bortezomib plus Rd (VRd) regimens have evolved over the past few years as therapies of choice for the first-line treatment of these patients. A breakthrough came with daratumumab, which increased response rates, extended median progression-free survival (PFS) and overall survival (OS) in the absence of significantly increased toxicity when added to the above regimens.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Retrospective data, Journal:  Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany. (Pubmed Central) -  Apr 26, 2024   
    Retrospective cohort study of patients with COPD and ?1 prescription for single-inhaler triple therapy (SITT; fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI] or beclomethasone dipropionate/glycopyrronium bromide/formoterol [BDP/GLY/FOR]) or multiple-inhaler triple therapy (MITT), using data from the AOK PLUS German sickness fund (1 January 2015-31 December 2019)...Overall, 97.9% of prevalent triple therapy users and 86.4% of incident triple therapy initiators received maintenance treatment in the 24-month pre-index period. In a real-world setting in Germany, triple therapy was most frequently used after maintenance therapy in patients with recent exacerbations, in line with current treatment recommendations.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Dexamethasone in anesthesia practice: A narrative review. (Pubmed Central) -  Apr 26, 2024   
    It has been used successfully in fascial blocks. It significantly decreases fatigue, shivering and postoperative sore throat and improves quality of recovery.
  • ||||||||||  Eladur (bupivacaine) / Amneal
    Clinical, Journal:  The effect of adding dexmedetomidine or dexamethasone to bupivacaine-fentanyl mixture in spinal anesthesia for cesarean section. (Pubmed Central) -  Apr 26, 2024   
    This study investigated the effect of adding either dexmedetomidine or dexamethasone to the intrathecal bupivacaine-fentanyl mixture on the postoperative analgesia duration, after elective cesarean section...The time to the first request of morphine rescue analgesia was recorded, in addition to the total dose of morphine consumed in the first 24 h after surgery, the postoperative numerical rating score (NRS), and maternal and fetal outcomes...There was an insignificant difference between the control and dexamethasone groups. The use of dexmedetomidine as an additive to bupivacaine-fentanyl mixture in spinal anesthesia for cesarean section prolonged the postoperative analgesia and decreased the postoperative opioid consumption in comparison to the addition of dexamethasone or normal saline.
  • ||||||||||  Retrospective data, Journal, Surgery:  Thoracic spinal anesthesia with intrathecal sedation for lower back surgery: a retrospective cohort study. (Pubmed Central) -  Apr 26, 2024   
    No significant complications were detected. Thoracic spinal anesthesia incorporating adjuvants such as midazolam, clonidine or dexmedetomidine, and dexamethasone demonstrates not only efficient conditions for spine surgery, a favorable safety profile, high patient satisfaction, and intrathecal sedation but also effective opioid-free pain management.
  • ||||||||||  odronextamab (REGN1979) / Regeneron, Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma, Rituxan (rituximab) / Roche
    Trial completion date, Trial initiation date, Trial primary completion date:  Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Apr 26, 2024   
    P2/3,  N=210, Not yet recruiting, 
    Thoracic spinal anesthesia incorporating adjuvants such as midazolam, clonidine or dexmedetomidine, and dexamethasone demonstrates not only efficient conditions for spine surgery, a favorable safety profile, high patient satisfaction, and intrathecal sedation but also effective opioid-free pain management. Trial completion date: Oct 2032 --> May 2033 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Oct 2030 --> May 2031
  • ||||||||||  Barhemsys (intravenous amisulpride) / Eagle Pharma
    Enrollment open, Trial completion date, Trial primary completion date:  Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients (clinicaltrials.gov) -  Apr 25, 2024   
    P2/3,  N=410, Recruiting, 
    In patients with mild to moderate CTS, LCI resulted in better improvement in the BCTQ scores at 1 Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS
    Quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma (TENDMM): A systematic review and meta-analysis. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_6890;    
    Background: Immunomodulatory drugs, proteasome inhibitors plus dexamethasone are the standard triplet induction regimen for TENDMM...Four trials (2303 patients) assessed the addition of anti-CD-38 mAbs and three (1243 patients) assessed anti-SLAMF7 mAb, elotuzumab to the triplet regimen... Quadruplet therapy improved PFS, ORR, and MRD rates compared to triplet regimen and has demonstrated promising benefits to be considered the new standard of care for TENDMM patients.
  • ||||||||||  dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology, Rituxan (rituximab) / Roche
    Effect of AVM0703 treatment on the limitations of R-CHOP and survival in a model applicable to ABC subtype DLBCL. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4994;    
    AVM+RCHOP demonstrated anti-tumor activity in A20 lymphoma mice, with reduced toxicity, compared to RCHOP. Larger preclinical studies are underway to confirm the activity of AVM0703+RCHOP against RCHOP resistant ABC DLBCL, and the potential to reduce total RCHOP exposure to only 3 cycles while maintaining or improving efficacy.